| abstract |
The present invention relates to the transdermal delivery of cannabinoids. Preferably, the cannabinoids are delivered via an occlusive body (i.e., a patch) to alleviate harmful side effects and avoid gastrointestinal (first-pass) metabolism of the drug by the patient. One aspect of the invention provides a pharmaceutical composition comprising one or more cannabinoid selected from the group consisting of: cannabinol, cannabidiol, nabilone, levonantradol, (-)-HU-210, (+)-HU-210, 11-hydroxy-Δ9-THC, Δ8- THC-1 T-oic acid, CP 55,940, 2-Methyl-1 -propyl-1 H-indol-3-yl-1 -naphthalenylmethanone, 1 -pentyl-3-(1 -naphthoyl) indole, 3-(1 \1 kiimethylb'utyl)-1 -deoxy-Δ8-THC, and R(+)-WIN 55,212-2; and one or more permeation enhancer selected from the group consisting of: propylene glycol moηolaurate, diethylene glycol monoethyl ether, dipropylene glycol, polyoxyethylene 6 caprylic triglyceride, polyoxyethylene 6 capric triglyceride, a polyoxyethylene glyceride, PPG-5 ceteth-20, an oleoyl macrogolglyceride, lauroyl macrogolglyceride, a caprylocaproyl macrogolglyceride, oleic acid, isopropyl myristate, linoleic acid, and an oleyl alcohol. |